Mainz Biomed Bv Stock Beneish M Score

MYNZ Stock  USD 7.32  0.40  5.78%   
This module uses fundamental data of Mainz Biomed to approximate the value of its Beneish M Score. Mainz Biomed M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Mainz Biomed Piotroski F Score and Mainz Biomed Altman Z Score analysis.
  
At this time, Mainz Biomed's Net Debt is fairly stable compared to the past year. Long Term Debt is likely to rise to about 1 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 4.1 M in 2024. At this time, Mainz Biomed's Shareholders Equity Per Share is fairly stable compared to the past year. Debt To Equity is likely to rise to 1.93 in 2024, whereas Price To Sales Ratio is likely to drop 19.99 in 2024.
At this time, it appears that Mainz Biomed BV is an unlikely manipulator. The earnings manipulation may begin if Mainz Biomed's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Mainz Biomed executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Mainz Biomed's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-4.58
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables

1.54

Focus
Asset Quality

0.67

Focus
Expense Coverage

0.97

Focus
Gross Margin Strengs

1.05

Focus
Accruals Factor

0.97

Focus
Depreciation Resistance

0.97

Focus
Net Sales Growth

0.68

Focus
Financial Leverage Condition

1.56

Focus

Mainz Biomed Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Mainz Biomed's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables372.2 K354.5 K
Sufficiently Up
Slightly volatile
Total Revenue611.1 K895.5 K
Way Down
Slightly volatile
Total Assets10.4 M15.4 M
Way Down
Slightly volatile
Total Current Assets8.2 MM
Significantly Down
Slightly volatile
Non Current Assets Total6.8 M6.4 M
Sufficiently Up
Slightly volatile
Property Plant Equipment367.4 K388.4 K
Notably Down
Slightly volatile
Depreciation And Amortization1.1 MM
Sufficiently Up
Slightly volatile
Selling General Administrative8.9 M13.4 M
Way Down
Slightly volatile
Total Current Liabilities9.7 M9.2 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total2.7 M2.9 M
Moderately Down
Slightly volatile
Short Term Debt5.5 M5.2 M
Sufficiently Up
Slightly volatile
Long Term DebtMM
Fairly Up
Slightly volatile

Mainz Biomed BV Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Mainz Biomed's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Mainz Biomed in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Mainz Biomed's degree of accounting gimmicks and manipulations.

About Mainz Biomed Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

1.09 Million

At this time, Mainz Biomed's Depreciation And Amortization is fairly stable compared to the past year.

Mainz Biomed ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mainz Biomed's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mainz Biomed's managers, analysts, and investors.
Environmental
Governance
Social

About Mainz Biomed Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Mainz Biomed BV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mainz Biomed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mainz Biomed BV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Mainz Stock Analysis

When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.